New Stroke Drug Shows Promise for Treatment Within 48 Hours
A phase 3 trial found loberamisal improved 90-day functional recovery in selected ischemic-stroke patients treated within 48 hours.
Latest Health news and articles from Nexora News & Insights.
A phase 3 trial found loberamisal improved 90-day functional recovery in selected ischemic-stroke patients treated within 48 hours.